AstraZeneca (AZN)
(Delayed Data from NSDQ)
$77.35 USD
+0.48 (0.62%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $77.36 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$77.35 USD
+0.48 (0.62%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $77.36 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth F Momentum D VGM
Zacks News
Here's Why Astrazeneca (AZN) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Lilly (LLY) to Build $2.5B Plant to Meet Increased Drug Demand
by Zacks Equity Research
Through this expansion, Eli Lilly (LLY) intends to expand its global manufacturing footprint to support the rising demand for its diabetes and obesity portfolio.
Pharma Stock Roundup: FDA Okays AZN's Capivasertib & MRK's Keytruda Expanded Use
by Kinjel Shah
FDA approves AstraZeneca's (AZN) new breast cancer drug, Truqap, and the expanded use of Merck's (MRK) Keytruda in a gastric cancer indication
AstraZeneca's (AZN) Capivasertib Gets FDA Nod for Breast Cancer
by Zacks Equity Research
AstraZeneca's (AZN) capivasertib gets approval in combination with Faslodex for HR-positive, HER2-negative metastatic breast cancer.
AstraZeneca's (AZN) Imfinzi Early-Stage Lung Cancer Study Fails
by Zacks Equity Research
AstraZeneca's (AZN) PACIFIC-2 study on Imfinzi fails to achieve statistical significance for the primary endpoint of progression-free survival.
Ionis (IONS) Early-Stage Genetic Disorder Data Shows Promise
by Zacks Equity Research
Preliminary data from a phase I/IIa study on Ionis' (IONS) pipeline candidate, ION582, shows encouraging EEG and clinical observations in a phase I/IIa study.
Here is What to Know Beyond Why AstraZeneca PLC (AZN) is a Trending Stock
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Astrazeneca (AZN). This makes it worthwhile to examine what the stock has in store.
Ironwood's (IRWD) Q3 Earnings Miss Mark, Linzess Volume Rises
by Zacks Equity Research
Ironwood's (IRWD) third-quarter 2023 earnings miss estimates, while revenues beat the same. Linzess collaboration revenues drive the top line.
AstraZeneca (AZN) Buys Global Rights to Oral Obesity Candidate
by Zacks Equity Research
To cash in on the rising demand for obesity drugs, AstraZeneca (AZN) in-licenses exclusive rights to ECC5004, a novel oral GLP-1RA therapy, from private Chinese biotech Eccogene.
AstraZeneca (AZN) Beats on Q3 Earnings & Sales, Ups 2023 View
by Zacks Equity Research
AstraZeneca (AZN) beats third-quarter estimates for earnings and sales. The company raises its sales and EPS guidance for 2023.
Jobless Claims Decreased More Than Expected
by Zacks Equity Research
Jobless Claims Decreased More Than Expected
Pre-Markets Strong on Higher Bond Rates, Mixed Earnings
by Mark Vickery
While this positive sentiment is welcome, we note bond yield rates going higher this morning.
Astrazeneca (AZN) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
The headline numbers for Astrazeneca (AZN) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
AstraZeneca (AZN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Higher sales of AstraZeneca's (AZN) key medicines, Lynparza, Tagrisso, Imfinzi and Farxiga, are likely to have driven sales in the third quarter, partially offset by lower sales of legacy drugs.
Unlocking Q3 Potential of Astrazeneca (AZN): Exploring Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Astrazeneca (AZN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2023.
Ionis (IONS) Q3 Loss Wider Than Expected, Sales Beat Estimates
by Zacks Equity Research
Ionis (IONS) incurs a wider-than-expected third-quarter loss. Sales beat estimates. The company re-affirms its previously issued financial guidance for 2023.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Astrazeneca (AZN) Rises But Trails Market: What Investors Should Know
by Zacks Equity Research
In the most recent trading session, Astrazeneca (AZN) closed at $63.23, indicating a +0.46% shift from the previous trading day.
Can High Benefits and Expenses Affect Cigna (CI) Q3 Earnings?
by Zacks Equity Research
Cigna's (CI) third-quarter results are likely to reflect growth in medical customers and pharmacy revenues.
Amgen (AMGN) Beats on Q3 Earnings Beat, Lags Sales, Ups View
by Zacks Equity Research
Amgen (AMGN) beats Q3 estimates for earnings but misses on sales. Following the acquisition of Horizon Therapeutics, it raises earnings and sales guidance for 2023.
Is Trending Stock AstraZeneca PLC (AZN) a Buy Now?
by Zacks Equity Research
Astrazeneca (AZN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Will Lower CenterWell Profit Hurt Humana's (HUM) Q3 Earnings?
by Zacks Equity Research
Humana's (HUM) third-quarter results are likely to reflect higher investment income and premiums.
Sanofi (SNY) Beats on Q3 Earnings, to Spin-Off Consumer Unit
by Zacks Equity Research
Sanofi (SNY) beats third-quarter estimates for earnings but misses the same for sales. It announces plans to separate its Consumer unit into a new public listed company.
Merck (MRK) Q3 Earnings Top Estimates, COVID Drug Boosts Sales
by Zacks Equity Research
Merck (MRK) beats Q3 estimates for earnings and sales. It raises its 2023 guidance. Stock rises in pre-market.
Eli Lilly (LLY) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
On Eli Lilly's (LLY) third-quarter conference call, investor focus is likely to be on the sales of its new diabetes drug, Mounjaro.